Phase I and pharmacokinetic study of intravenous irinotecan plus oral ciclosporin in patients with fuorouracil-refractory metastatic colon cancer

• Published in: Journal of clinical oncology Vol. 21; no. 6; p. 1125
• Main Authors: Chester, John D, Joel, Simon P, Cheeseman, Susan L, Hall, Geoffrey D, Braun, Michael S, Perry, Jackie, Davis, Theresa, Button, Christopher J, Seymour, Matthew T
• Format: Journal Article
• Language: English
• Published: United States 15.03.2003
• Subjects: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic - pharmacology; Antineoplastic Agents, Phytogenic - administration & dosage; Antineoplastic Agents, Phytogenic - pharmacokinetics; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics; Antineoplastic Combined Chemotherapy Protocols - pharmacology; Camptothecin - administration & dosage; Camptothecin - analogs & derivatives; Camptothecin - pharmacokinetics; Colonic Neoplasms - blood; Colonic Neoplasms - drug therapy; Colonic Neoplasms - pathology; Cyclosporine - administration & dosage; Cyclosporine - pharmacology; Drug Resistance, Neoplasm; Female; Fluorouracil - pharmacology; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Treatment Outcome

To assess the safety and toxicity profile of escalating doses of intravenous irinotecan, in combination with a fixed dose of oral ciclosporin (Cs) and to determine the pharmacokinetic profile of irinotecan and its metabolites. Patients with fluorouracil-refractory metastatic colorectal cancer receiv...